193 related articles for article (PubMed ID: 21998480)
21. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
22. Valacyclovir. New indication: for genital herpes, simpler administration.
Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous HSV-2 infection with serial recurrences at multiple sites.
Dacko A; Don PC; Weinberg JM
Int J Dermatol; 2002 Feb; 41(2):109-11. PubMed ID: 11982649
[No Abstract] [Full Text] [Related]
24. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
26. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
27. Valacyclovir to reduce transmission of genital herpes simplex virus infection.
Drew WL
J Infect Dis; 2009 Mar; 199(6):916. PubMed ID: 19239344
[No Abstract] [Full Text] [Related]
28. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
29. Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Brown TJ; McCrary M; Tyring SK
J Am Acad Dermatol; 2002 Oct; 47(4):581-99. PubMed ID: 12271305
[TBL] [Abstract][Full Text] [Related]
30. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
31. HSV therapy and HIV-1 reduction.
Eisenhut M
N Engl J Med; 2007 May; 356(22):2323-4; author reply 2324. PubMed ID: 17542070
[No Abstract] [Full Text] [Related]
32. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
33. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
[TBL] [Abstract][Full Text] [Related]
34. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
[TBL] [Abstract][Full Text] [Related]
35. Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection.
Williams JR; Jordan JC; Davis EA; Garnett GP
Sex Transm Dis; 2007 Mar; 34(3):123-31. PubMed ID: 17325600
[TBL] [Abstract][Full Text] [Related]
36. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
37. Herpes simplex virus infection.
Whitley RJ
Semin Pediatr Infect Dis; 2002 Jan; 13(1):6-11. PubMed ID: 12118847
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.
Tyring SK; Douglas JM; Corey L; Spruance SL; Esmann J
Arch Dermatol; 1998 Feb; 134(2):185-91. PubMed ID: 9487210
[TBL] [Abstract][Full Text] [Related]
39. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.
Johnston C; Saracino M; Kuntz S; Magaret A; Selke S; Huang ML; Schiffer JT; Koelle DM; Corey L; Wald A
Lancet; 2012 Feb; 379(9816):641-7. PubMed ID: 22225814
[TBL] [Abstract][Full Text] [Related]
40. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists, number 57, November 2004. Gynecologic herpes simplex virus infections.
ACOG Committee on Practice Bulletins--Gynecology
Obstet Gynecol; 2004 Nov; 104(5 Pt 1):1111-8. PubMed ID: 15516420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]